Next |
home / stock / idra / idra message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $ACGN 87% v16,0M c3.11 f8,423M H5.37 ML1.51 | znewcar1 | investorshangout | 05/04/2023 3:38:30 AM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 04/30/2023 9:21:14 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 04/15/2023 3:35:21 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 02/27/2023 12:32:32 AM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 02/21/2023 10:41:02 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 02/05/2023 11:05:29 PM |
znewcar1: $IDRA 20% v626K c.5569 f62,355M H.56 ML.215 YL.3369 | znewcar1 | investorshangout | 01/04/2023 9:23:46 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 12/18/2022 10:21:07 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 10/23/2022 5:16:27 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 08/31/2022 9:57:24 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 07/17/2022 9:44:36 PM |
Idera Pharmaceutical ($IDRA) | mick | investorshub | 06/05/2022 5:50:51 AM |
Idera Pharmaceutical ($IDRA) | mick | investorshub | 05/01/2022 8:03:49 PM |
Why isnt this dying dog dead yet? What | urge2surge | investorshub | 04/23/2022 2:50:06 PM |
Idera Pharmaceutical ($IDRA) | mick | investorshub | 03/12/2022 8:04:58 PM |
Stinky poop pile eh? Big fat nothing burger...lol. | urge2surge | investorshub | 02/16/2022 10:38:17 PM |
Someone needs to take this dying dog to | urge2surge | investorshub | 02/08/2022 10:14:47 PM |
Idera Pharmaceutical ($IDRA) | mick | investorshub | 02/06/2022 11:01:22 PM |
Last one out, turn off the lights. Nothing | urge2surge | investorshub | 02/05/2022 11:23:27 AM |
Lmao..what a dog pile.. A dead dog with | urge2surge | investorshub | 02/02/2022 4:30:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...